Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional - and often ineffective - advice to "eat ...

If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Crumpets? And oats? Surely there’s been some mistake. You don’t need a BTech in home economics to understand why Coco Pops ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

The strongest influence of cardiovascular risk and obesity on reduced brain volume is seen between 55 and 64 years o ...

Certain types of porridge, crumpets and breakfast cereals are included in a list of products that fall under a new junk food ...